Author Manuscript Published OnlineFirst on September 12, 2012; DOI: 10.1158/1535 cytotoxic to triple negative breast cancer cells and worked through a pathway that did not require wild-type p53 for cytoxicity. Therefore, 8-NH 2 -Ado should be considered for the treatment of triple negative breast cancers that are chemotherapy resistant.
Introduction:
Treatment of metastatic and triple negative breast cancer remains a challenge in the clinical setting. Gemcitabine is a nucleoside analogue that is approved by the FDA to be used in combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after they have received anthracycline chemotherapy. Gemcitabine activates DNA damage pathways that signal to the tumor suppressor p53 (1) , and a functional p53 pathway improves gemcitabine cytotoxicity (2) . The p53 protein is a tumor suppressor that activates transcription of many downstream target genes and thereby controls cell growth and cell death (3) . However, in 70 percent of human cancers the p53 gene is found mutated (4) . In breast cancer, p53 is often found mutated in triple negative and metastatic tumors (5) . Therefore identifying nucleoside analogue chemotherapeutic treatments that can kill breast cancers independently of activating the p53-pathway is an important aspect of improving cancer treatments.
The identification of drugs that can inhibit the growth of triple negative breast cancers with mutant p53 is an understudied area. Therefore we have worked to identify a compound that inhibits breast cancer proliferation regardless of the hormone receptor status or the mutant p53 status. We hypothesized that the nucleoside analogue, 8-amino-adenosine (8-NH 2 -Ado) would inhibit breast cancer cell proliferation independently of the p53 pathway.
In normal cells wild-type p53 is the guardian of the genome, however inactivation of p53 through either mutation or interactions with oncogenic proteins, plays a large role in tumor promotion (4) . Currently breast cancers resistant to chemotherapy are treated with drugs that activate DNA damage pathways (6) .
DNA damaging drugs activate the p53-pathway and studies indicate that wildtype p53 can be responsible for the vast number of side effects associated with the death of normal cells during DNA damage (7) . Recent work with a panel of breast cancer cell lines suggests that combining the DNA-damaging agent gemcitabine with a PARP inhibitor (that blocks DNA repair and inhibits all cell checkpoints) enhances the cytotoxic outcome on cancer cells (8) (9) (10) . However a chemotherapeutic nucleoside that does not activate the p53 pathway might be more effective.
Unique and promising RNA-directed treatments for myeloma are the nucleoside analogues 8-chloro-adenosine (currently in phase I trials) and 8-NH 2 -Ado (11, 12) . Importantly, 8-NH 2 -Ado is more cytotoxic to myeloma cancer cells than to normal human lymphocytes (13, 14) . Moreover, 8-NH 2 -Ado is an RNAdirected nucleoside analogue that inhibits transcription and polyadenylation (12, 15) . Adenosine analogues accumulate in cells as triphosphates and decrease the endogenous ATP pool (12) . Preclinical studies on multiple myelomas have been very encouraging, (13, 14, 16, 17 MTT: Toxic effects of the drugs were determined by measuring the mitochondrial activity of each cell line using the tetrazolium dye-based micro-titration assay to measure mitochondrial dehydrogenases activity (20) . Cells were seeded at 1. The ELISA steps were carried out as described by the manufacturer's direction with slight modifications. The final step was modified to stop color development by the addition of 100 μl of 5% SDS. Detection was carried out at 415 nm against a substrate solution blank. Enrichment factor = mU of the drug treated (dying/dead cells)/ mU of the corresponding control.
Quantitative reverse transcription-PCR (qRT-PCR)
Standard procedures from the manufacturers were used for these assays. RNA was isolated using QIAshredder columns and RNeasy Mini Kit (Qiagen). 5 µg of RNA was used for cDNA synthesis using High Capacity cDNA Archive Kit reagents (Applied Biosystems). 150 ng of cDNA was combined with Taqman Universal Master Mix and Applied Biosystems Assays on Demand primers/probes for p21 (Hs00355782_m1) or actin (4352935E). PCR reaction was carried out in 7500 Sequence Detection System (Applied Biosystems) and actin was used as the normalizer.
Whole cell protein extraction
Cells were lysed in RIPA buffer (0.1% SDS, 1% NP-40, 0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Tris-Cl pH8) with 1 mM PMSF, 
Lysosomal Staining
Labeling of the live cells adherent to the cover slips with red-fluorescent LysoTracker dye and blue-fluorescent Hoechst dye was performed according to manufacturer's protocol and images were taken on Olympus Fluorescent Microscope.
RNA interference and transfections
For siRNA experiments, MDA-MB-231 cells were seeded in media without penicillin-streptomycin and allowed to attach overnight. Cells were transfected at 60% confluency with 100 nM of atg7 siRNA smart pool or non-targeted siRNA from Dharmacon for 6 hrs using (26, 27) . We addressed the possibility that 8-NH 2 -Ado increased autophagy in MDA-MB-231 cells until the point of cell death.
8-NH 2 -Ado increases the autophagy markers in MDA-MB-231 cells but does not require autophagy for cytotoxicity.
While autophagy is initially a cell survival pathway where cytosolic components are encapsulated in double-membrane vesicles, it can also be used as a death pathway if pushed to cannibalize the cell (28, 29) . We examined the increase of two different autophagic markers in the cells before and after 8- assay and the appearance of floating cells (Figures 6C and 6D) . We also knocked down atg7 to inhibit autophagy and saw no increase in MTT activity ( Figures 6E and 6F) . The knockdown of atg7 increases MCF-7 cells resistance to photodynamic therapy suggesting that it helps the cells to die (33) . However 8- 
Discussion:
Apoptosis is a well-described cell death pathway but the relationship between autophagy and cell death is controversial (34) . The autophagy gene beclin 1 is a haploinsufficient tumor suppressor and increased expression of Beclin 1 in MCF-7 cells promotes autophagy and inhibits the formation of human breast tumors in mouse models (35) . Autophagic cell death is sometimes described as programmed cell death II, and has been suggested as a new target for cancer therapy (36) . However it has been clearly documented that autophagy maintains cellular homeostatsis and can have both antitumor and tumor promoting properties (37) . Recently autophagy has been shown to promote ras- (39) . This suggests feasibility of using these drugs at the needed dosage in human patients. Additionally previous studies show that 8-NH 2 -Ado is not cytotoxic to normal lymphocytes (13, 14) . When we tested reduction mammoplasty cells they were sensitive to 8-NH 2 -Ado in the culture setting but these cells were very difficult to grow and therefore were not a good indicator of overall cytotoxicity to a patient (Polotskaia and Bargonetti unpublished data). The outcomes of 8-chloro-adenosine studies should help to pave the way for the consideration of 8-NH 2 -Ado as an agent to treat aggressive breast cancer. 
